Theriva Biologics, Inc. (TOVX) Balance Sheet

The steady decline in total assets suggests that the company is consuming its capital base to support ongoing R&D, which limits the runway for future clinical milestones. This trajectory indicates that the business model remains entirely dependent on external capital injections to maintain operations.

The rapid deterioration of the current ratio highlights the precarious nature of the company's liquidity position. Investors should monitor this trend closely, as the narrowing buffer suggests that any unexpected delays in clinical trial enrollment or regulatory hurdles could necessitate immediate and potentially dilutive financing.

The persistent erosion of equity underscores the value-destructive nature of the company's current funding model. The reliance on equity financing to bridge the gap between research and commercialization suggests that existing shareholders face continued dilution risk until a transformative partnership or clinical success is achieved.